The Cancer Genome Atlas (TCGA) Clinical Data Reporting Form - Lung		Barcode Internal Use Only	
Tissue Source Site (TSS) Name:			1. Completed By:
TSS Iden		Date:	
			2. Completed By:
	nical Data Definition: All of thes to "qualify" the tumor specimen for		Date:
Tier 1 C	Clinical Data (Page 1 of 3)		
Tier #	Data Element Label	Entry Alternatives	caBIG Definition
1:01	TSS Unique Patient #		
1: 02	Organ of Origin – Lung	Brain Lung Ovary	Whole organ level. Text term for originating or primary anatomic site of the disease/condition under investigation or review. (2735776)
1:03	Histological Type: Lung Confirm squamous carcinoma	Yes No	The description of the microscopic pattern indicating the degree of similarity between the tumor and the tissue of origin.
1:04	Gender	Male Female	Text designations that identify gender. Gender is described as the assemblage of properties that distinguish people on the basis on their social roles. [Explanatory Comment 1: Identification of gender is based upon self-report and may come from a form, questionnaire, interview, etc. (2200604)
1: 05	Date of Birth		Date on which the patient/participant was born. (2201154)
1:06	Reserved for Future Use	N/A	
1: 07	Tobacco smoking history indicator	Current Former Never	Text indicator to represent a person's tobacco smoking, the act of puffing and/or inhaling smoke from a lit tobacco cigarette, cigar, or pipe. (2436233)
1:08	Date of initial pathologic diagnosis		The date this disease was first diagnosed. (58204)
1:09	Neo-adjuvant (pre-operative) therapy	Yes No	Therapy includes any of the following: Radiation/ Chemo/ Immuno/ Hormonal Therapy. The yes/no indicator to ask whether any treatment was given the patient prior to surgery.
1: 10	Date of Surgical Resection		The date of a surgical procedure.

TCGA Clinical Data Reporting Form - Lung TSS Name:TSS Identifier #: TSS Unique Patient #		Barcode Internal Use Only			
	Tier 1 Clinical Data (Page 2 of 3)				
Tier #	Data Element Label	Entry Alternatives	caBIG Definition		
1: 11A	Tumor stage (pathological) LUNG AJCC System (Definitions are 6 th edition nomenclature)	Primary Tumor (T) TX TO Tis T1 T2 T3 Regional Nodes (N) NX NO N1 N2 N3 Distant Metastasis (M) MX MO			
1: 11B	Stage groupings (Definitions are 6 th edition nomenclature)	☐ M1 ☐ Occult (O) ☐ I A ☐ IB ☐ IIA ☐ II B ☐ III A ☐ III B ☐ III B ☐ IV			
1:12	Tumor Grade For squamous of the Lung: N/A as a Tier 1 element (see q. 2.12)	NA			
1: 13	Complete Excision (RO) Adjuvant (Post-operative) Irradiation therapy	Yes (RO) No (R1) Unknown Yes No	 RO: Surgical margins free of tumor grossly and microscopically. No evidence of residual disease following surgery. R1: Residual disease present (local, regional, or distant) New CDE to be created Yes/no indicator to ask if therapeutic application if radiation was initiated to treat disease following surgery to remove tumor and associated malignant tissue. 		

TCGA Clinical Data Reporting Form - Lung TSS Name: TSS Identifier #: TSS Unique Patient #		Barcode Internal Use Only	
Tier 1 (Clinical Data (Page 3 of 3)		
Tier #	Data Element Label	Entry Alternatives	caBIG Definition
1: 15	Adjuvant (Post-operative) Chemotherapy	Yes No	Did the patient receive adjuvant chemotherapy?
1:16	Adjuvant (Post-operative) Immunotherapy	Yes No	Yes/no indicator that asks whether the patient has previous immunotherapy as preventive treatment for an earlier stage for this cancer.
1: 17	Adjuvant (Post-operative) Hormonal therapy	Yes No	Yes/no/unknown indicator whether adjuvant hormone therapy was administered following surgery
1:18	Adjuvant (Post-operative) "Targeted" Molecular Therapy	Yes No	
1: 19	Date of first Recurrence after therapy		The date when the return or spread of cancer was first diagnosed.
1: 20	Date of last contact (clinical evaluation)		The date of the last successful contact with the patient, family member, or caregiver to establish responses for 1:21 and 1:22 below
1:21	Vital Status	Living	Test summary level description of patient / participant survival status
1: 22	Date of Death		The actual date of a patients/participants death

Comments:

Principal Investigator Signature

Name

ΜM	DD	ΥY

		Form - Lung TSS Identifier #:		Barcode Internal Use Only
	TSS Unique Patient #		1 Completer	1 Dut
Tissue S	Source Site (TSS) Name:		1. Completed	л Бу .
	TSS Identifier #:			
	que Patient #		2. Completed	d By:
	linical Data Definition: Desirab tion for clinical correlation analyse:		Dat	
Tier 2	Clinical Data (Page 1 of 9)		
Tier #	Data Element Label	Entry Alternatives		caBIG Definition
2:02	Anatomic Organ Sub- Division a. Brain b. Lung c. Ovary	Brain N/A	dleLower er	Anatomic organ: Text term for originating of primary anatomic site of the disease/condition under investigation or review. (2735776) For tumors in paired organs, designates the side on which was obtained (2007875)
2:07	Tobacco current use	No: # years quit	YRS	Pack years: The number of packs (of cigarettes) smoked per day times the number of years smoked (2546448) No. years quit: Total time period during when an individual didn't smoke, expressed in number of years. (2181903) Pack years: (256448)
2:08	Method of initial pathologic diagnosis	 Cytology (e.g. Peritoneal or Fine needle aspiration biops Incision biopsy Excisional biopsy Tumor resection Other method, specify: Unknown 		Method: Name of the procedure used to secure tissue for the original pathologic diagnosis. (2757941) Other method: Test to describe a method used to secure tissue for an original pathologic diagnosis that is different from other methods. (2757948)
2: 09A	Neo-adjuvant (pre-operative) Irradiation therapy	□ No □ Yes Type: □ Impants □ Radioisot □ Other Specify Source:	opes ton	Name of the neo-adjuvant radiation therapy type administered preoperatively to an individual (2757957) Other type: Name of neo-adjuvant radiation therapy type administered preoperatively that is different from other identified types (2757964) Start date: Date neo-adjuvant preoperative radiation therapy began. (2759142) Stop date: Date neo-adjuvant preoperative radiation therapy ended. (2759144) Dosage: Text description of the total dose of radiation therapy administered to an individual expressed as a dosage amount and unit of measure (UOM). (2721441) Fractions: The total number of radiation therapy sessions (fractions) which the patient has completed to receive the required radiation dose to primary treatment fields. (61465)

	TCGA Clinical Data Reporting F		Barcode Internal Use Only
	TSS Unique Patient #		
Tier 2 C	Clinical Data (Page 2 of 9)		
Tier #	Data Element Label	Entry Alternatives	caBIG Definition
2: 09B	Data Element Label Neo-adjuvant (pre-operative) Chemotherapy	Entry Alternatives No Yes Root of administration: Oral Intravenous (IV) Intra-peritoneal (IP) IV and IP Other: Specify	Start Date: The date on which prior neo- adjuvant chemotherapy treatment started. (62690) Stop Date: The total number of cycles (courses) administered to the patient of a protocol specified drug or therapy agent. (62590) Drug Used: Name of a neo-adjuvant agent administered to an individual. (2758212) Total Dosage given: Agent total cumulative dose (1515)
2: 09C	Neo-adjuvant (pre-operative) Hormone therapy	NO Yes Start Date: M M D D Y Y End Date: M M D D / Y Y # of cycles give: D Drugs used Total dose given 1 2 3	Start Date: the start date of neo-adjuvant hormone therapy. (2199659) Stop Date: The date neo-adjuvant hormonal therapy ended. (2199665) Drugs Used: Name of the neo-adjuvant hormonal prior therapy agent administered to an individual. (2758641) # of cycles: The total number of cycles (courses) administered to the patient f a protocol specified drug of therapy agent. (1515)

	TCGA Clinical Data Reporting F TSS Name: TSS Unique Patient #	Form - Lung _ TSS Identifier #:	Barcode Internal Use Only		
Tier 2	Tier 2 Clinical Data (Page 3 of 9)				
Tier #	Data Element	Entry Alternatives	caBIG Definition		
2: 09D	Neo-adjuvant (pre-operative) Immunotherapy	No Yes Start Date: M M D D End Date: M M D D # of cycles give:	Start Date: Date that neo-adjuvant immunotherapy began. (2758923) Stop Date: Date that neo-adjuvant immunotherapy ended. (2759147) Drug Used: Name of a neo-adjuvant immunotherapy agent administered to an individual. (2759151) Total Dosage given: Agent total cumulative dose (1515)		
2: 11A	Additional information	Drugs used Total do	dose (1515)		
	beyond AJCC manual 6 th edition is included here in preparation for edition 7: (T): Size	T): size in cm			
	Nodules in Ipsilateral (non- primary) lung lobe:	Yes No Unknown			
2: 11C	Metastasis: Plural effusion with malignant cells	Yes No Unknown			
	Distant Metastasis	Yes No Unknown			
2: 11D	Vascular Invasion	Negative for venous inv Positive for venous inva Unknown for venous in	sion invasion was detected by surgery or presence in tumor specimen. (64358 information to be derived from pathology reports (CDE # 64358)		
2: 11E	Lymphatic Invasion	Negative for lymphatic Positive for lymphatic ir Unknown for lymphatic	present on small or thin-walled vessels suggesting lymphatic involvement. (64171)		
2: 12	Tumor Grade	GX: Grade cannot be asse G1: Well differentiated G2: Moderately different G3: Poorly differentiated G4: Undifferentiated	abnormality of cancer cells, a measure of differentiation and aggressiveness.		

	TCGA Clinical Data Reporting F TSS Name: TSS Unique Patient #		Barcode Internal Use Only
Tier 2 C	Clinical Data (Page 4 of 9)		
Tier #	Data Element	Entry Alternatives	caBIG Definition
2:13	Tumor Margins	N/A	Some tumors may have additional specifics in the definitions of margin involved with tumor
2:14	Neo-adjuvant (pre-operative) Irradiation therapy	□ No □ Yes Type: □ Impants □ Radioisotopes □ Combinaton □ Other Specify Source:	Name of the neo-adjuvant radiation therapy type administered preoperatively to an individual (2757957) Other type: Name of neo-adjuvant radiation therapy type administered preoperatively that is different from other identified types (2757964) Start date: Date neo-adjuvant preoperative radiation therapy began. (2759142) Stop date: Date neo-adjuvant preoperative radiation therapy ended. (2759144) Dosage: Text description of the total dose of radiation therapy administered to an individual expressed as a dosage amount and unit of measure (UOM). (2721441) Fractions: The total number of radiation therapy sessions (fractions) which the patient has completed to receive the required radiation dose to primary treatment fields. (61465)
2:15	Adjuvant (Post-operative) Chemotherapy	No Yes Root of administration: Oral Intravenous (IV) Intra-peritoneal (IP) IV and IP Other: Specify	Start Date: the start date for previous chemotherapy administered as preventive treatment for an earlier stage of this cancer. (2285) Stop Date: the end date for previous chemotherapy administered as preventive treatment for an earlier stage of this cancer. (2287) # of Cycles: The total number of cycles (courses) administered to the patient of a protocol specified drug or therapy agent. (62590) Drug Used: the name of the agent or regimen of adjuvant Cytotoxic chemotherapy that was administered. (2464267) Total Dose given: Agent total cumulative dose (1515)

	TCGA Clinical Data Reporting F			Barcode
	TSS Name:	_TSS Identifier #:		Internal Use Only
	TSS Unique Patient #			
Ļ	Clinical Data (Page 5 of 9)			
Tier #	Data Element	Entry Alternatives		caBIG Definition
2:16	Adjuvant (Post-operative) Immunotherapy	No Yes Start Date: / / / M M D D End Date: / / / M M D D # of cycles give: / / Drugs used Total of 1	Y Y Y Y Y Y	Start Date: The start date for previous immunotherapy administered as preventive treatment for an earlier stage of this cancer. (2293) Stop Date: The end date for previous immunotherapy administered as preventive treatment for an earlier stage of this cancer. (2295) Drug Used: Name of a adjuvant immunotherapy agent administered to an individual.[Manually-curated] (2759176) # of Cycles: The total number of cycles (courses) administered to the patient of a protocol specified drug or therapy agent. (62590) Total Dose given: Agent total cumulative dose (1515)
2: 17	Adjuvant (Post-Operative) Hormone therapy	No Yes Start Date: / / / / / / / / / / / / / / / / / / /	/	
2:18	Adjuvant (Post-operative) Targeted Molecular Therapy	NO Yes Start Date: / / / / / / / / / / / / / / / / / / /		

	TCGA Clinical Data Reporting I	Form - Lung	Barcode			
		TSS Identifier #:	Internal Use Only			
	TSS Unique Patient #					
Tier 2 Clinical Data (Page 6 of 9)						
Tier #	Data Element	Entry Alternatives	caBIG Definition			
2:21	Vital Status A. Living B. Dead	Living Tumor Free With Tumor Unknown Tumor	The state or condition of an individual's neoplasm at a particular point in time. (2759550) Status			
		Dead U Tumor Free With Tumor Unknown Tumor	The state or condition of an individual's neoplasm at a particular point in time. (2759550)			
2: 00A	Race	 American Indian or Alaska Niperson having origins in any of the peoples of North and South America (Central America), and who maintain affiliation or community attachment) Asian (A person having origins in an original peoples of the Far East, Southeas or the Indian subcontinent including, for example, Cambodia, China, India, Japan, Malaysia, Pakistan, the Philippine Islands Thailand, and Vietnam) White (A person having origins in any original peoples of Europe, the Middle Econorth Africa) Black or African American (A person having origins in any of the black racial g Africa. Terms such as "Haitian" or "Negrou used in addition to "Black or African American (A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or othe Islands) Not Reported (Not provided or avai Unknown (Could not be determined unsure) 	original including ns tribal y of the st Asia, Korea, s, y of the ist, or on roups of " can be prican.") slander iginal er Pacific lable)			
	Ethnicity	 Not Hispanic or Latino (A person n meeting the definition for Hispanic or Lati Hispanic or Latino (A person of Me Puerto Rican, Cuban, Central or South An or other Spanish culture or origin, regard race) Not reported (Not provided or avai. Unknown (Could not be determined unsure) 	tino) xican, nerican less of lable)			

	TCGA Clinical Data Reporting F TSS Name: TSS Unique Patient #	Form - Lung _ TSS Identifier #:	Barcode Internal Use Only		
	Tier 2 Clinical Data (Page 7 of 9)				
Tier #	Data Element	Entry Alternatives	caBIG Definition		
2: 00B	Patient Performance Status Scale	 Not Recorded a. Karnofsky Score 100 asymptomatic 80-90 symptomatic by fully ambulatory 60-70 symptomatic but in bed less then 50% of day 40-50 symptomatic, in bed more than 50% of the day, but not bed ridden 20-30 bed ridden 	Performance status scale, representing the functional capabilities of a person. (2003853)		
		 b. Eastern Cancer Oncology Group (ECOG) 0 asymptomatic 1 symptomatic by fully ambulatory 2 symptomatic but in bed less then 50% of day 3 symptomatic, in bed more than 50% of the day, but not bed ridden 4 bed ridden 			
2: 00C	Second Surgery for tumor recurrence or progression	None Local site procedure No Yes M M D D Y Yes M M D D Y Y Lymph Node procedure No Yes M D D Y Y Metastasis procedure No Yes M D D Y Y	Indicator: The yes/no/unknown indicator that asks whether the recurrence was treated by surgery. (2199761) Procedure: Name of the second surgical procedure performed for recurrent or progressive disease. (2759612) Date: Date of the second surgical procedure performed for recurrent or progressive disease. (2759616)		
2: 00D	Additional treatment of tumor recurrence/progression Irradiation therapy	No Yes Type: □ External beam □ Impants Radioisotopes □ Combinaton Other Specify Source:	 Indicator: the yes/no indicator related to the additional administration of the use of highenergy radiation from x-rays, gamma rays, neutrons, and other sources to kill cancer cells and shrink tumors after the return of a disease. (2650648) Type: Particular kind of radiation therapy administered after the recurrence or progression of disease. (2759630) Start Date: Date that additional radiation therapy began after the recurrence or progression of disease. (2759632) Stop Date: Date that additional radiation therapy ended for the recurrence or progression of disease. (2759634) Dosage: Text description of the total dose of radiation therapy administered to an individual expressed as a dosage amount and unit of measure (UOM). (2721441) Fractions: The total number of radiation therapy sessions (fractions) which the patient has completed to receive the required radiation dose to primary treatment fields. (61465) 		

	TOCA Clinical Data Data data		Deveede					
	TCGA Clinical Data Reporting		Barcode					
	TSS Name: TSS Unique Patient #		Internal Use Only					
-								
Tier 2 C	Tier 2 Clinical Data (Page 8 of 9)							
Tier #	Data Element	Entry Alternatives	caBIG Definition					
2: 00E	Additional treatment for tumor recurrence/ progression Chemotherapy	No Yes Root of administration: Oral Intravenous (IV) Intra-peritoneal (IP) IV and IP Other: Specify	Indicator: the yes/no indicator related to the additional administration of chemotherapy after the return of a disease after a period of remission. (2650626) Start Date: Date that additional chemotherapy ended for the recurrence of progression of disease. (2759815) Drugs: Name of the additional chemotherapy agent administered to an individual after disease recurrence or progression. (2759817) # of cycles: the total number of cycles (courses) administered to he patient of a protocol specified drug or therapy agent. (62590) Total dose given: Agent total cumulative dose (1515)					
2:00F	Additional treatment of tumor recurrence/progression Immunotherapy	No Yes Start Date: M M D D Y Y End Date: M M D D Y Y End Date: M M D D Y Y # of cycles give: Drugs used Total dose given 1 2 3	Indicator: the yes/no indicator related to the additional administration of various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level after ther return of a disease after a period of remission or new disease. (2650646) Start Date: Date that additional hormonal therapy began after the recurrence or progression of disease. (2759819) Stop Date: Date that additional hormonal therapy ended for the recurrence or progression of disease. (2759821) # of Cycles: The total number of cycles (courses) administered to the patient of a protocol specified drug or therapy agent. (62590) Drugs Used: Name of the additional hormonal agent administered to an individual after disease recurrence or progression. (2759823) Total dose given: Agent total cumulative dose (1515)					

	TCGA Clinical Data Reporting F TSS Name: TSS Unique Patient #	Form - Lung _ TSS Identifier #:	Barcode Internal Use Only				
Tier 2 Clinical Data (Page 9 of 9)							
Tier #	Data Element Label	Entry Alternatives	caBIG Definition				
2: 00G	Additional treatment for tumor recurrence/ progression Hormone therapy	$\square No$ $\square Yes$ Start Date: $\square / \square / \square / \square$ $M M D D Y Y$ End Date: $\square / \square / \square / \square$	Indicator: the yes/no indicator related to the additional administration of various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level after ther return of a disease after a period of remission or new disease. (2759828) Start Date: Date that additional				
		# of cycles give: Drugs used Total dose given 1 2 3 	hormonal therapy began after the recurrence or progression of disease. (2759830) Stop Date: Date that additional hormonal therapy ended for the recurrence or progression of disease. (2759832) # of Cycles: The total number of cycles (courses) administered to the patient of a protocol specified drug or therapy agent. (62590) Drugs Used: Name of the additional hormonal agent administered to an individual after disease recurrence or progression. (2759834) Total dose given: Agent total cumulative dose (1515)				
2:00H	Additional treatment of tumor recurrence/progression Targeted molecular therapy	No Yes Start Date: M D Y End Date: M M D Y # of cycles give: Drugs used Total dose given 1 2 3	Definitions and descriptions as previously described.				

Comments:

		$\Box\Box'$		
Principal Investigator Signature	Print Name	MM	DD	ΥY